In vitro evaluation of dioscin and protodioscin against ER-positive and triple-negative breast cancer

Women’s breast cancer is one of the most significant healthcare issues for the human race that demands a proactive strategy for a cure. In this study, the cytotoxic activity (MTT assay) of two natural steroidal compounds, protodioscin and dioscin, against two major subtypes of human breast cancer es...

Full description

Bibliographic Details
Main Authors: Najat Bouchmaa, Reda Ben Mrid, Youssef Bouargalne, Sana Ajouaoi, Francesco Cacciola, Rachid El Fatimy, Mohamed Nhiri, Abdelmajid Zyad
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2023-01-01
Series:PLoS ONE
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9910703/?tool=EBI
_version_ 1811166138221985792
author Najat Bouchmaa
Reda Ben Mrid
Youssef Bouargalne
Sana Ajouaoi
Francesco Cacciola
Rachid El Fatimy
Mohamed Nhiri
Abdelmajid Zyad
author_facet Najat Bouchmaa
Reda Ben Mrid
Youssef Bouargalne
Sana Ajouaoi
Francesco Cacciola
Rachid El Fatimy
Mohamed Nhiri
Abdelmajid Zyad
author_sort Najat Bouchmaa
collection DOAJ
description Women’s breast cancer is one of the most significant healthcare issues for the human race that demands a proactive strategy for a cure. In this study, the cytotoxic activity (MTT assay) of two natural steroidal compounds, protodioscin and dioscin, against two major subtypes of human breast cancer estrogen receptor-positive (ER-positive)/MCF-7 and triple-negative breast cancer (TNBC)/MDA-MB-468), was assessed. The clonogenic capacity was evaluated using the clonogenic assay. Oxidative stress was determined by measuring the formation of malondialdehyde and H2O2 and the assessment of total antioxidant enzyme activities (SOD, GPx, GR, and TrxR). Protodioscin and dioscin were highly cytotoxic against the tested cell lines (1.53 μM <IC50< 6 μM) with low cytotoxicity on normal cells (PBMC; IC50 ≥ 50 μM). Interestingly, these compounds were responsible for a substantial decrease in the clonogenic capacity of both cell lines. Moreover, dioscin was able to reduce the cell motility of the invasive breast cancer cells (MDA-MB-468). At the molecular level, the two treatments resulted in an increase of reactive oxygen species. Notably, both compounds were responsible for decreasing the enzymatic activities of glutathione reductase and thioredoxin reductase. On the basis of such considerations, protodioscin and dioscin may serve as promising natural compounds to treat TNBC and ER-positive breast cancer through the induction of oxidative stress.
first_indexed 2024-04-10T15:47:41Z
format Article
id doaj.art-a715c1950fed4fb58d97b6aa4052c863
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-04-10T15:47:41Z
publishDate 2023-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-a715c1950fed4fb58d97b6aa4052c8632023-02-12T05:31:11ZengPublic Library of Science (PLoS)PLoS ONE1932-62032023-01-01182In vitro evaluation of dioscin and protodioscin against ER-positive and triple-negative breast cancerNajat BouchmaaReda Ben MridYoussef BouargalneSana AjouaoiFrancesco CacciolaRachid El FatimyMohamed NhiriAbdelmajid ZyadWomen’s breast cancer is one of the most significant healthcare issues for the human race that demands a proactive strategy for a cure. In this study, the cytotoxic activity (MTT assay) of two natural steroidal compounds, protodioscin and dioscin, against two major subtypes of human breast cancer estrogen receptor-positive (ER-positive)/MCF-7 and triple-negative breast cancer (TNBC)/MDA-MB-468), was assessed. The clonogenic capacity was evaluated using the clonogenic assay. Oxidative stress was determined by measuring the formation of malondialdehyde and H2O2 and the assessment of total antioxidant enzyme activities (SOD, GPx, GR, and TrxR). Protodioscin and dioscin were highly cytotoxic against the tested cell lines (1.53 μM <IC50< 6 μM) with low cytotoxicity on normal cells (PBMC; IC50 ≥ 50 μM). Interestingly, these compounds were responsible for a substantial decrease in the clonogenic capacity of both cell lines. Moreover, dioscin was able to reduce the cell motility of the invasive breast cancer cells (MDA-MB-468). At the molecular level, the two treatments resulted in an increase of reactive oxygen species. Notably, both compounds were responsible for decreasing the enzymatic activities of glutathione reductase and thioredoxin reductase. On the basis of such considerations, protodioscin and dioscin may serve as promising natural compounds to treat TNBC and ER-positive breast cancer through the induction of oxidative stress.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9910703/?tool=EBI
spellingShingle Najat Bouchmaa
Reda Ben Mrid
Youssef Bouargalne
Sana Ajouaoi
Francesco Cacciola
Rachid El Fatimy
Mohamed Nhiri
Abdelmajid Zyad
In vitro evaluation of dioscin and protodioscin against ER-positive and triple-negative breast cancer
PLoS ONE
title In vitro evaluation of dioscin and protodioscin against ER-positive and triple-negative breast cancer
title_full In vitro evaluation of dioscin and protodioscin against ER-positive and triple-negative breast cancer
title_fullStr In vitro evaluation of dioscin and protodioscin against ER-positive and triple-negative breast cancer
title_full_unstemmed In vitro evaluation of dioscin and protodioscin against ER-positive and triple-negative breast cancer
title_short In vitro evaluation of dioscin and protodioscin against ER-positive and triple-negative breast cancer
title_sort in vitro evaluation of dioscin and protodioscin against er positive and triple negative breast cancer
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9910703/?tool=EBI
work_keys_str_mv AT najatbouchmaa invitroevaluationofdioscinandprotodioscinagainsterpositiveandtriplenegativebreastcancer
AT redabenmrid invitroevaluationofdioscinandprotodioscinagainsterpositiveandtriplenegativebreastcancer
AT youssefbouargalne invitroevaluationofdioscinandprotodioscinagainsterpositiveandtriplenegativebreastcancer
AT sanaajouaoi invitroevaluationofdioscinandprotodioscinagainsterpositiveandtriplenegativebreastcancer
AT francescocacciola invitroevaluationofdioscinandprotodioscinagainsterpositiveandtriplenegativebreastcancer
AT rachidelfatimy invitroevaluationofdioscinandprotodioscinagainsterpositiveandtriplenegativebreastcancer
AT mohamednhiri invitroevaluationofdioscinandprotodioscinagainsterpositiveandtriplenegativebreastcancer
AT abdelmajidzyad invitroevaluationofdioscinandprotodioscinagainsterpositiveandtriplenegativebreastcancer